Funding Support


Current Grants



Molecular Link Between Metabolic Syndrome and Prostate Cancer

NIH/NCI 2 R01 CA131945-06A1– PI ($ 2,129,315.00)

This project will establish a molecular connection between the metabolic syndrome and the aggressive form of prostate cancer that arises in these individuals, and provide a biomarker for the identification of prostate cancer with AMPK inactivation. These patients will likely benefit from novel therapeutics strategies directed at metabolic targets.


Targeting the p110beta isoform of PI3 kinase in prostate cancer

NIH/NCI R01CA187918 – CPI ($3,794,633)

The experiments proposed in this grant are designed to facilitate bringing a novel class of drugs, inhibitors of the p110β isoform of PI3 kinase, to the clinic for use in patients with Pten null prostate cancer.


DF/HCC SPORE in Prostate Cancer

NIH/NCI P50 CA90381 (Loda, M/DFCI)

Co-PI with S. Balk, BIDMC

Core A , Administration Core ($230,966)

The purpose of the Core is to ensure the coordination of the SPORE components and to provide oversight and leadership of the scientific, administrative and fiscal aspects of the SPORE. Specific Aims: 1) Monitor research progress and plan for the future; 2) Foster collaborative research within and between SPORE’s; 3) Integrate the DF/HC Prostate Cancer SPORE into the structure of the DF/HCC; 4) Provide necessary resources and fiscal oversight; and 5) Promote rapid dissemination of significant research findings and free and open communication and resource exchange between the DF/HCC SPORE and other institutions.

Core C, Tissue and Pathology Core ( $158,491)

The Core will continue to supervise the frozen tissue and serum bank efforts that have been ongoing for the past 10 years as well as construct from the corresponding archival tissue microarrays to improve and streamline all immunohistochemical analyses

Project 1, Tumor and circulating markers as links between obesity and lethal prostate cancer ( $255,398)

The study aims to elucidate mechanisms underlying the link between obesity and lethal prostate cancer and identify patient subgroups more susceptible to the obesity milieu

Project 2, Gleason-based mRNA and metabolomic profiling to predict prostate cancer progression ( $188,759)

The hypothesis of this study is that metabolites in serum associated with Gleason grade may indicate the presence of higher-grade tumor not detected at biopsy and could serve as a biomarker for monitoring disease progression of active surveillance patients.


DF/HCC SPORE in Gastrointestinal Cancer: Core 2 – Tissue and Pathology Core

NIH/NCI P50 CA127003 (Fuchs, C/DFCI)

Core Director ($157,039)

The main goal of the Specialized Program of Research Excellence (SPORE) of Gastrointestinal Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of gastrointestinal malignancies.


IHC MET Assay Phase 2 Clinical Trials

HHSN261200800001E (Loda, M/ DFCI)


Principal Investigator ($18,084)

The objective of this initiative is to ensure that the most important biomarker, imaging and quality of life studies can be initiated in a timely manner in association with Phase 3 and certain Phase 2 clinical trials. This BIQSFP funding provides a unique opportunity to study an integrated biomarker across 4 Phase II studies utilizing the same agent (cabozantinib). The assay, immunohistochemistry (IHC) of total MET expression, will be completed in the Center for Molecular Oncologic Pathology (CMOP) at DFCI for all 4 studies.

The goals of this project are to assess whether AMPK activation inhibits castration-resistant prostate cancer (CRPC) growth in vivo. To investigate the biographic relevance of combining AMPK activators or FASN inhibitors with AR signaling inhibitors as a synergic therapeutic strategy for CRPC.


Androgen receptor-regulated non-conical WNT signaling in prostate

R21 (Jia, L./BWH) ($4,912)

American Cancer Society

We hypothesize that AR/WNT7B/PKCδ signaling is critical for PCa growth and progression. Overproduction of WNT7B in PCa increases incidence of bone metastasis by promoting osteoblast differentiation, creating a more favorable microenvironment for PCa growth. Dr. Loda will be examining the human prostate cancer tissue microarray and mouse xenograft tissues for specific protein expression (WNT7B and PKC delta).


Pharmacologic Inhibition of Lipogenesis Suppresses AR and its Splice Variants to Inhibit Progression of Castration Resistant Prostate Cancer

DOD (Loda/Plymate/Dehm) ($222,262 DFCI only)

PCRP Impact Award

The specific aims of this project are 1) Determine the role of FASN inhibition on enzalutamide and abiraterone resistance, where resistance is due to AR-Vs expression; 2) Generation of organoids from human PDX models evaluated and characterized in aim 1 and from primary and metastatic human prostate cancer; 3): Mechanism of AR regulation by FASN inhibition.